UTA Family 3 Final Exam
1. 2017 ACC/AHA guidelines: normal BP: <120 / <80
2. 2017 ACC/AHA guidelines: elevated BP: 120-129/ <80
3. 2017 ACC/AHA guidelines: stage 1 HTN: 130--89
4. 2017 ACC/AHA guidelines: stage 2 HTN: e 140/ e 90
5. What is recommended for white coat hypertension?: -
lifestyle modification
- annual ABPM or HBPM
6. What is recommended for masked hypertension?: - lifestyle
modification
- start HTN medication
7. What is recommended for elevated BP?: - lifestyle
modification
- annual ABPM
8. What is secondary hypertension?: - drug resistant/induced
hypertension
- exacerbation of previously controlled hypertension
- accelerated/malignant hypertension
- unprovoked or excessive hypokalemia
9. What are common causes of secondary hypertension?: -
renal disease
- aldosteronism
- OSA
- drug and alcohol induced
10. What are non-pharmacological interventions for
hypertension?: - weight
loss
- DASH diet
- sodium reduction
- potassium supplementation
- reduce alcohol consumption
11. 2017 ACC/AHA guidelines: clinical CVD and BP e 130 / e
80: use BP lowering
1
, meds
12. 2017 ACC/AHA guidelines: primary prevention in adults
10 yr ASCVD risk
of e 10%: use BP lowering meds
13. 2017 ACC/AHA guidelines: 10 yr risk < 10% and SBP e
140/90: use BP
lowering meds
14. 2017 ACC/AHA guidelines: normal BP reassessment:
yearly
15. 2017 ACC/AHA guidelines: elevated BP reassessment: 3-
6 months
16. 2017 ACC/AHA guidelines: stage 1 HTN reassessment
and 10 yr ASCVD <
10%: 3-6 months
17. 2017 ACC/AHA guidelines: stage 2 HTN reassessment:
one month until goal
BP met, then 3-6 months
18. 2017 ACC/AHA guidelines: stage 1 HTN reassessment
and 10 yr ASCVD >
10%: one month until BP goal met, then 3-6 months
19. What hypertensive medications should not be prescribed
simultaneously?:
- ACE
- ARB
- Renin Inhibitor
20. 2017 ACC/AHA guidelines: first line agents: - thiazide
diuretics
- CCBs
- ACE
- ARBs
21. 2017 ACC/AHA guidelines: initiation of drug therapy in
stage 2 HTN: initiate
drug therapy with 2 first line medications of different classes as
separate agents or
combo drug
2
1. 2017 ACC/AHA guidelines: normal BP: <120 / <80
2. 2017 ACC/AHA guidelines: elevated BP: 120-129/ <80
3. 2017 ACC/AHA guidelines: stage 1 HTN: 130--89
4. 2017 ACC/AHA guidelines: stage 2 HTN: e 140/ e 90
5. What is recommended for white coat hypertension?: -
lifestyle modification
- annual ABPM or HBPM
6. What is recommended for masked hypertension?: - lifestyle
modification
- start HTN medication
7. What is recommended for elevated BP?: - lifestyle
modification
- annual ABPM
8. What is secondary hypertension?: - drug resistant/induced
hypertension
- exacerbation of previously controlled hypertension
- accelerated/malignant hypertension
- unprovoked or excessive hypokalemia
9. What are common causes of secondary hypertension?: -
renal disease
- aldosteronism
- OSA
- drug and alcohol induced
10. What are non-pharmacological interventions for
hypertension?: - weight
loss
- DASH diet
- sodium reduction
- potassium supplementation
- reduce alcohol consumption
11. 2017 ACC/AHA guidelines: clinical CVD and BP e 130 / e
80: use BP lowering
1
, meds
12. 2017 ACC/AHA guidelines: primary prevention in adults
10 yr ASCVD risk
of e 10%: use BP lowering meds
13. 2017 ACC/AHA guidelines: 10 yr risk < 10% and SBP e
140/90: use BP
lowering meds
14. 2017 ACC/AHA guidelines: normal BP reassessment:
yearly
15. 2017 ACC/AHA guidelines: elevated BP reassessment: 3-
6 months
16. 2017 ACC/AHA guidelines: stage 1 HTN reassessment
and 10 yr ASCVD <
10%: 3-6 months
17. 2017 ACC/AHA guidelines: stage 2 HTN reassessment:
one month until goal
BP met, then 3-6 months
18. 2017 ACC/AHA guidelines: stage 1 HTN reassessment
and 10 yr ASCVD >
10%: one month until BP goal met, then 3-6 months
19. What hypertensive medications should not be prescribed
simultaneously?:
- ACE
- ARB
- Renin Inhibitor
20. 2017 ACC/AHA guidelines: first line agents: - thiazide
diuretics
- CCBs
- ACE
- ARBs
21. 2017 ACC/AHA guidelines: initiation of drug therapy in
stage 2 HTN: initiate
drug therapy with 2 first line medications of different classes as
separate agents or
combo drug
2
